Novo Nordisk exceeds expectations: profits sprout thanks to Wegovy!

Novo Nordisk exceeds expectations: profits sprout thanks to Wegovy!

The Danish pharmaceutical company Novo Nordisk is experiencing a high -altitude flight: for 2024, the company recorded impressive sales of 290 billion Danish crowns (over 38 billion euros), which corresponds to an increase of 25 percent compared to the previous year. These figures are the result of the success of their diabetes and obesity medication, in particular the much-noticed active ingredient Wegovy, which also causes a sensation for investors- as krone.at reported.

In the last quarter of 2024, the net profit exceeded the expectations of the analysts with 28.23 billion crowns (around 3.78 billion euros) that had assumed 26.09 billion crowns. Overall, profit rose to 100.99 billion crowns (approx. 13.53 billion euros), also over the forecast 99.14 billion. The sales of the Wegovy, which exploded by a whopping 107 percent - is particularly remarkable - a clear indicator of the constant success of the product, such as Wallstreet-online.de reported.

forecasts for the future